Arkolith/Insider Trading/FBRX/Form 4

Wagner Paul A.

SEE REMARKS, DirectorForte Biosciences, Inc. (FBRX) · full profile →Form 4 · filed Apr 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2024Option exercise(M)31K—$01.9M
Apr 1, 2024Tax withholding(F)2K$0.71$2K1.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2024Option exercise(M)31K—$0344K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-009857) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML